Alkem Laboratories appoints Rajpal Singh Rana as SVP - Marketing & Sales

1 min read     Updated on 03 Aug 2026, 06:50 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Alkem Laboratories Limited appointed Rajpal Singh Rana as Senior Vice President - Marketing & Sales for the Acute Cluster on August 3, 2026. Rana brings over 30 years of industry experience and holds an MBA from Sikkim Manipal University. The appointment was disclosed under Regulation 30 of the SEBI LODR Regulations.

powered bylight_fuzz_icon
47308815

*this image is generated using AI for illustrative purposes only.

Alkem Laboratories Limited has appointed Rajpal Singh Rana as Senior Vice President - Marketing & Sales for the Acute Cluster, effective August 3, 2026. The company disclosed the senior management change to the stock exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This leadership addition aims to strengthen the company’s commercial operations in its acute care segment.

The appointment was communicated to the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 3, 2026. Divya Mewani, Vice President – Legal & Deputy Company Secretary at Alkem Laboratories, signed the disclosure letter. The company stated that the information is also available on its official website.

Appointment Details

Rana’s contract term is defined as continuing for as long as he remains in the employment of the company. The filing did not disclose any specific fixed tenure or performance-linked exit clauses. There are no disclosed relationships between Rana and the company’s directors.

Particulars Details
Name Rajpal Singh Rana
Designation Senior Vice President - Marketing & Sales
Effective Date August 3, 2026
Term Duration of employment

Professional Profile

Rana is an experienced pharmaceutical professional with over 30 years of experience in marketing and sales. Before joining Alkem Laboratories, he worked with various other pharmaceutical companies. He holds an MBA in Marketing from Sikkim Manipal University and a B.Sc. in Physics, Chemistry & Mathematics from Delhi University.

Regulatory Context

The disclosure was made under Regulation 30(2) of the SEBI LODR Regulations, read with Schedule III, Part A. The company also referenced the SEBI Master Circular bearing number HO/49/14/14(7)2025-CFDPOD2/1/3762/2026 dated January 30, 2026, regarding the format and content of such disclosures. The appointment does not involve any change in the board composition or promoter holding.

Historical Stock Returns for Alkem Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-0.77%+1.30%+2.46%+2.55%+13.43%+63.88%

How is Alkem Laboratories planning to leverage Rajpal Singh Rana's 30 years of experience to differentiate its acute care products in a competitive market?

What specific revenue growth targets or market share expansions has Alkem set for the Acute Cluster under Rana's new leadership?

Will this appointment signal a broader strategic shift in Alkem's marketing approach, such as increased focus on digital sales channels or key account management?

Alkem Laboratories dispatches Annual Report web-link for FY25-26

2 min read     Updated on 30 Jul 2026, 07:08 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Alkem Laboratories Limited has informed shareholders via letter about accessing the FY25-26 Annual Report online, targeting those without registered emails. The disclosure aligns with SEBI regulations ahead of the August 27 AGM. Key dates include the dividend record date on August 7 and voting eligibility on August 20.

powered bylight_fuzz_icon
46951117

*this image is generated using AI for illustrative purposes only.

Alkem Laboratories has dispatched letters providing the web-link and exact path to access its Annual Report for the financial year 2025-26 (FY25-26). The communication was sent to shareholders who had not registered their email addresses with the company, its depository participants, or its Registrar to an Issue & Share Transfer Agent (RTA), MUFG Intime India Private Limited, as of the cut-off date on July 10, 2026. This disclosure ensures that all stakeholders can access critical financial information despite the absence of digital contact details.

The intimation was filed with the Bombay Stock Exchange and the National Stock Exchange of India Limited on July 30, 2026, in compliance with Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Annual Report is also available on the company’s website at www.alkemlabs.com , under the investors section. Shareholders are encouraged to update their email addresses through their depository participants or by communicating directly with the RTA to facilitate future electronic communications and support the company’s green initiative.

AGM and Dividend Details

The Annual Report pertains to the period leading up to the company’s 52nd Annual General Meeting (AGM), scheduled for August 27, 2026, at 11:00 AM IST. The meeting will be conducted via Video Conferencing or Other Audio Visual Means. Shareholders holding shares as of the record date, August 20, 2026, are eligible to vote. Remote e-voting will be open from August 24 to August 26, 2026.

Additionally, the company has fixed August 7, 2026, as the record date for determining dividend entitlements for FY25-26. If approved by members during the AGM, the final dividend will be paid on or after September 1, 2026. Investors are advised to submit necessary documents for Tax Deducted at Source (TDS) compliance under the Income-Tax Act, 2025, if applicable.

Key Date Event
July 10, 2026 Cut-off date for email registration status
July 30, 2026 Dispatch of Annual Report web-link letters
August 7, 2026 Record date for dividend entitlement
August 20, 2026 Record date for AGM voting rights
August 24-26, 2026 Remote e-voting window
August 27, 2026 52nd Annual General Meeting

What This Means for Shareholders

The dispatch of physical letters with web-links highlights the ongoing transition towards digital communication in corporate governance while maintaining inclusivity for shareholders who have not opted for electronic modes. For investors, ensuring their contact details are updated with depository participants is crucial to receiving timely information about dividends, meetings, and other material announcements. The availability of the Annual Report online allows immediate access to the company’s financial performance, including the Q1FY27 results which showed a 48% rise in net profit to ₹432.10 crore, providing context for the full-year outlook presented in the report.

Historical Stock Returns for Alkem Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-0.77%+1.30%+2.46%+2.55%+13.43%+63.88%

How might Alkem Laboratories' FY25-26 full-year financial performance, detailed in the newly released Annual Report, compare against the strong 48% net profit growth seen in Q1FY27?

What specific strategic initiatives or capital allocation plans is management likely to present at the upcoming 52nd AGM to sustain long-term growth?

Will the final dividend proposed for FY25-26 reflect a change in payout ratio compared to previous years, and how might this impact investor sentiment?

More News on Alkem Laboratories

1 Year Returns:+13.43%